Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (8)

2023

  1. Impact of retinal fluid-free months on outcomes in neovascular age-related macular degeneration: A treatment agnostic analysis of the hawk and harrier studies

    Retina, Vol. 43, Núm. 4, pp. 632-640

2022

  1. Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD

    Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 260, Núm. 6, pp. 1843-1856

2021

  1. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design

    Future Oncology, Vol. 17, Núm. 12, pp. 1459-1472

2020

  1. RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study

    Retina (Philadelphia, Pa.), Vol. 40, Núm. 9, pp. 1673-1685

  2. Reply

    Retina (Philadelphia, Pa.)

2017

  1. Evaluation of a community-based hypertension improvement program (ComHIP) in Ghana: data from a baseline survey

    BMC Public Health, Vol. 17, Núm. 1

2013

  1. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme

    British Journal of Ophthalmology, Vol. 97, Núm. 9, pp. 1161-1167

2011

  1. Why a Bayesian approach to safety analysis in pharmacovigilance is important

    Pharmaceutical Statistics, Vol. 10, Núm. 6, pp. 554-559